This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n8http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1662
rdf:type
owl:Class
rdfs:label
Indinavir Sulfate
rdfs:subClassOf
_:vb682416 _:vb682414 _:vb682415 nci:C97366
nci:A6
nci:C66877
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance Organic Chemical
nci:P108
Indinavir Sulfate
nci:P175
697197
nci:P207
C0700483
nci:P210
157810-81-6
nci:P319
771H53976Q
nci:P322
FDA
nci:P329
42594
nci:P330
42594
nci:P350
C36H47N5O4.H2SO4
nci:P366
Indinavir
nci:P368
CHEBI:5899
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, (1(1S,2R,5(S))-, sulfate (1:1) (salt)</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>MK-639</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>DRG-0233</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Indinavir Sulfate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Crixivan</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>L-735,524</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>INDINAVIR SULFATE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>771H53976Q</n0:source-code></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic antiviral agent. Indinavir selectively binds to the active site of human immunodeficiency virus (HIV) protease and inhibits its activity, preventing the protease-mediated cleavage of gag-pol viral polyproteins; as a result immature, noninfectious virions are produced.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1662
owl:sameAs
n7:771H53976Q n8:N0000179614
n5:hasConcept
n6:M0329078
Subject Item
_:vb682414
rdf:type
owl:Restriction
owl:onProperty
nci:R122
owl:someValuesFrom
nci:C17573
Subject Item
_:vb682415
rdf:type
owl:Restriction
owl:onProperty
nci:R122
owl:someValuesFrom
nci:C46000
Subject Item
_:vb682416
rdf:type
owl:Restriction
owl:onProperty
nci:R122
owl:someValuesFrom
nci:C45999